



EDUCATIONAL OPPORTUNITIES

• **SEPT. 17-20, Providence**

American Assoc. of Neuro-muscular & Electro-diagnostic Medicine
Phone: (507) 288-0100
www.aanem.org

• **SEPT. 17-20, Montreal**

ACTRIMS-ECTRIMS-LACTRIMS Joint Meeting
Phone: 212-476-0452
E-mail: actrimns@nmss.org
www.actrimns.org

• **SEPT. 19-20, Halifax**

5th Atlantic Canada Stroke Conference
Phone: (902) 494-2061
E-Mail: cme@dal.ca

• **SEPT. 21-24, Salt Lake City**

ANA 133rd Annual Meeting
Phone: (952) 545-6284
E-mail: ana@llmsi.com
www.aneuroa.org

• **SEPT. 24-27, Vienna**

6th World Stroke Congress
Phone: 41-229-080-488
E-Mail: stroke2008@kenes.com

• **OCT. 17, Orlando**

Society of Neurosurgical Anesthesia and Critical Care Annual Meeting
Phone: (847) 825-5586
E-Mail: snacc@asahq.org

• **OCT. 18-25, Woods Hole, MA**

2008 Research Update in

Neuroscience for Neurosurgeons
E-mail: dempsey@neuro-surg.wisc.edu

• **NOV. 5-8, Santa Clara, CA**

Child Neurology Society (CNS) 37th Annual Meeting
Phone: (651) 486-9447
E-Mail: nationaloffice@childneurology-society.org

• **NOV. 7-9, Scottsdale**

Scottsdale Headache Symposium
Phone: (856) 423-0043
E-mail: ahsmtgs@talley.com
www.americanheadachesociety.org

• **NOV 15-19, Washington, DC**

Society for Neuroscience 38th Annual Meeting
Phone: (202) 462-6688
Email: info@sfn.org
www.sfn.org

• **DEC. 5-9, Seattle**

62nd Annual Meeting of the American Epilepsy Society
Phone: (860) 586-7505
E-Mail: csluboski@aesnet.org

• **DEC. 7-11, Scottsdale, AZ**

American College of Neuro-psychopharmacology
Phone: 615-324-2360

E-Mail: acnp@acnp.org

2009 Meetings:

• **JAN. 16-18, Orlando**

2009 American Academy of Neurology Regional Conference
Phone: (800) 879-1960 / (651) 695-2717

E-Mail: memberservices@aan.com

• **FEB. 11-14, Atlanta**

37th Annual Int'l Neuropsychological Society Meeting
Phone: (614) 263-4200
E-Mail: ins@osu.edu

• **MARCH 7-11, Charleston, SC**

American Society for Neurochemistry 2009 Annual Meeting
Phone: (407) 876-0750
E-Mail: amazing@iag.net

• **MARCH 12-15, Miami**

Winter Headache Symposium 2009
Phone: 856-423-0043

E-Mail: ahsmtgs@talley.com

• **MARCH 13-16, New York**

5th World Congress of the World Institute of Pain
E-Mail: wip@kenes.com
http://www.kenes.com/wip/

• **APRIL 25-MAY 2, Seattle**

AAN 61st Annual Meeting
Phone: (800) 879-1960
E-mail: membership@aan.com
www.aan.com

• **MAY 2-7, San Diego**

77th AANS Annual Meeting
Phone: (847) 378-0500 / 1-888-566-AANS (2267)
E-Mail: info@aans.org

• **SEPT. 11-14, Philadelphia**

4th International Headache Congress/51st Annual Scientific Meeting
Phone: (856) 423-0043
E-mail: ahsmtgs@talley.com

List Your Meeting in Practical Neurology

Send information to
Zac Haughn, Associate Editor:
zhaughn@avondalemedical.com
Fax: (610) 238-9053

Be sure to include the meeting title, topics, dates, location, and registration information. Also, include a contact for us to contact for more information, if needed.

PRACTICAL PEARLS

With “DoloTest,” VAS values are read in millimeters for pain, problems with moderate activities, problems with vigorous activities, problems doing one’s job, reduced energy and strength, mood (low spirits), reduced social activity, and sleep disturbance. On average it took subjects one minute, 49 seconds to fill out this tool. Initial results suggest that patients were able to use this tool easily. p. 45

Sometimes adolescents with tension headaches won’t recognize the degree of stress they endure. And rarely is stress evident in their mien. Teens may even deny they are under stress because they are high-achievers who don’t want to give the suggestion that they “can’t cut it.” p. 40


Treatment of disturbed nocturnal sleep begins with determining the factors involved. Sleep hygiene; sleep disorders, such as sleep apnea, PLMs, RBD, and depression; anxiety disorders; dementia; circadian rhythm disorders; and the effects of medications all need to be assessed in any patients who have PD and disturbed sleep or daytime sleepiness. p. 26



Results of a Phase II trial of a tau aggregation inhibitor, MTC, Rmethylthioninium chloride, (Rember, Tau RX) show it is the first disease modifying Alzheimer’s therapy study that obtained its pre-specified cognitive therapy target. p. 23

The use of anti-PD medications (particularly dopamine receptor agonists) has been the most widely identified risk factor for PD psychosis, though other risk factors discussed in the literature include older age, disease severity, sleep disturbance, cognitive impairment, dementia and/or depression. p. 47

Some high-achieving adolescents seem to be prone to migraines. Along with pressure to perform well, these patients may also be encouraged not to display emotions such as anger, potentially contributing to headaches. p. 42



A useful starting point for neurologists completing evaluations in civil and criminal matters is to become familiar with relevant ethical standards, practice guidelines, and policy statements. Three fundamental sources are: National Academy of Neuropsychology, American Academy of Clinical Neuro-psychology, and American Psychological Association’s Committee on Psychological Tests and Assessment. p. 16

CMS says it is contemplating a “Physician Compare” Website, similar to those now in place that allow the public to compare the performance of hospitals and other providers. CMS says it does not plan to make 2008 PQRI data publicly available at the individual physician or group practice level. p. 34

Advertising Index

Practical Neurology Vol. 7, No.9, September 2008

Athena Diagnostics	Elsevier
• Lab Services8	• Neurologic Clinics37
Bayer Healthcare	Rochester Electro-Medical, Inc.
• Betaseron51-52	• Monopolar Needles.....31
Boehringer Ingelheim	Serono
• Mirapex.....12-15	• Rebif.....2-4
Cadwell Laboratories	
• Technomed Needles19	

For advertising information, contact Thomas Gangemi, Publisher
Phone: (610) 238-9052, ext. 11 email: tgangemi@avondalemedical.com